Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world

Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola‐BR) was approved for treatment of transplant‐ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. Methods We analyzed 21 patients with R/R DLBCL to determine real‐life efficacy and safety of Pola‐BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). Results Median overall survival was 8.7 months, and progression‐free survival 3.8 months. The overall response rate was 33%. Grade 3–4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR‐T therapy in 19%. Conclusion Although the outcome of patients is worse than in GO29365 trial, the use of Pola‐BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant‐ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR‐T therapy.